TENX News and Press, Tenax Therapeutics Inc.

2026-03-10 17:15:05 ET William Blair analyst issues OUTPERFORM recommendation for TENX on March 10, 2026 06:25PM ET. The previous analyst recommendation was Outperform. TENX was trading at $14.51 at issue of the analyst recommendation. The overall analyst consensus : BUY...

A look at the top 10 most actives in the United States Decent Holding Inc. (DXST) rose 50.4% to $0.3986 on volume of 392,509,512 shares Elong Power Holding Limited (ELPW) fell 98.3% to $0.0637 on volume of 345,469,270 shares Longeveron Inc. (LGVN) rose 68.3% to $0.891 on volume of 248,906,9...

2026-03-10 07:28:06 ET More on Tenax Therapeutics Tenax Therapeutics: Some Future Potential Tenax Therapeutics: A Speculative Buy Tenax Therapeutics: How Lower Variance In Phase 3 Has "Loaded The Dice" For An Asymmetric Repricing Seeking Alpha’s Quant ...

Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 Initiated global Phase 3 LEVEL-2 clinical trial and opened long-term OLE study for patients to remain on drug CHAPEL HILL, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutic...

CHAPEL HILL, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary ...

2026-02-26 14:07:37 ET Shares of cardiopulmonary concern Tenax Therapeutics, Inc. ( TENX ) have roughly doubled since providing a corporate update and presenting with key opinion leaders on November 13, 2025. The company addressed its rationale for advancing oral levosimendan (T...

CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary t...

2026-01-09 01:51:30 ET My Approach to Pick Biotech Stocks Being acutely aware of the risks of investing in the notoriously risky biotech space, as a non-scientist, I have developed the following apparently simple but actually tough three criteria for picking life science stocks:...

2026-01-05 13:19:56 ET EQUITY RESEARCH: PHARMACEUTICALS Company: Tenax Therapeutics ( TENX ) Investment Rating: BUY Risk Profile: Speculative/ High Risk First Price Target (12-months): $25 Current Price = $11.05 Upside: 127% TE...

Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026 Global Phase 3 LEVEL-2 Study Initiated; Company Estimates Completion of Enrollment by...